Tafasitamab in combination with lenalidomide is approved for the treatment of adult patients with r/r diffuse large B-cell lymphoma (DLBCL) in the US. It has also been approved in Europe for the treatment of adult patients with relapsed DLBCL who are not eligible for autologous hematopoietic stem cell transplantation (ASCT).
NMPA has granted approval for tafasitamab in combination with lenalidomide for the treatment of adult patients with r/r DLBCL who are not eligible for ASCT. This is the first CD19 antibody approved for the treatment of r/r DLBCL in China.